EUCTR2011-003606-24-ES进行中（未招募）不适用
A 52-week, Double-Blind, Randomized, Placebo Controlled Parallel Group Study to Evaluate the Effect of Roflumilast 500 ?g on Exacerbation Rate in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Treated with a Fixed Dose Combination of Long-Acting Beta Agonist and Inhaled Corticosteroid (LABA/ICS)
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 2,300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion Criteria at Screening (Visit 1)
- •1. Male or female subjects at least 40 years of age
- •2. History of COPD (according to GOLD 2010) for at least 12 months prior to Screening (Visit 1) associated with chronic productive cough for 3 months in each of 2 consecutive years (with other causes of productive cough excluded). Only subjects with chronic bronchitis will be included.
- •3. Forced expiratory volume after 1 second (FEV1)/forced vital capacity (FVC) ratio (postbronchodilator) < 70% at Screening (Visit 1)
- •4. FEV1 (postbronchodilator)
- •5. At least two documented moderate or severe COPD exacerbations within 12 months prior to Screening (Visit 1)
- •6. Subjects must be on FDC LABA/ICS (Advair® 250/50?g 1 puff BID or, Symbicort® 160/4.5 ?g 2 puffs BID) concomitant treatment >or= 3 months prior to Screening (Visit 1)
- •7. Those subjects who were previously treated with LAMA must have been on a stable dose for >or= 3 months before Screening (Visit 1) and must continue on the same dose throughout the study
- •8. Former smoker (defined as smoking cessation at least 1 year ago) or current smoker both with a smoking history of at least 20 pack-years
- •9. Subjects must be able to perform repeatable pulmonary function testing for FEV1 according to ATS/ERS 2005 criteria
- •10. Women of childbearing potential with a negative urine pregnancy test at Screening with ongoing use of birth control from study start (Screening) to last subject visit (Visit 8)
- •11. Subjects judged by the Investigator to be physically capable of participating in a year-long study based on medical history, physical examination, ECG, and routine laboratory data evaluations
- •12. Subjects who understand the study procedures and are willing to participate in the study as indicated by signing the informed consent
- •Inclusion Criteria at Randomization (Visit 2)
- •13. No moderate or severe COPD exacerbations between Screening (Visit 1) and Randomization (Visit 2)
- •14. Tablet compliance >or= 80% and
- •15. Advair and Symbicort compliance of >or= 80% and
- •16. Subjects must have remained on the same COPD maintenance therapy between Screening (Visit 1) and Randomization (Visit 2) (ie, ICS/LABA or LAMA added onto FDC LABA/ICS)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 2070
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 230
排除标准
- •1. Severe or very severe COPD exacerbation and/or COPD exacerbations treated with antibiotics or systemic glucocorticosteroids within 4 weeks of Screening (Visit 1) (ie, subjects must be clinically stable)
- •2. Lower respiratory tract infection within 4 weeks of Screening (Visit 1)
- •3. Diagnosis of significant lung disease other than COPD (eg, history of primary bronchiecstasis, cystic fibrosis, bronchiolitis, lung resection, lung cancer, interstitial lung disease [eg, fibrosis, silicosis, sarcoidosis], or active tuberculosis, pulmonary thromboembolic disease), pulmonary resection or lung volume surgery during the
- •past 12 months, cystic fibrosis, Kartagener syndrome), post organ transplantation, or who are expected to require thoracotomy or other lung surgery during the study
- •4. Known alpha-1-antitrypsin deficiency
- •5. Current diagnosis of asthma (either controlled or uncontrolled)
- •6. Liver impairment Child-Pugh B or C and/or active viral hepatitis
- •7. Chronic use of oxygen therapy >or= 15 hours/day
- •8. Body mass index (BMI) >or= 45 kg/m2
- •9. Subjects who have participated in an acute pulmonary rehabilitation program within the previous 3 months. (Note: Subjects on a stable pulmonary rehabilitation exercise regimen for at least 6 weeks are not excluded)
- •10. Subjects with a history of suicidal behavior
- •11. Subjects with a screening Columbia Suicide Severity Rating Scale (C-SSRS) score of >or= 4 (suicidal ideation or behavior)
- •12. Subjects with clinically significant cardiovascular conditions including: myocardial infarction within the previous 6 months; newly diagnosed arrhythmia within the previous 3 months; unstable angina; unstable arrhythmia that has required changes in pharmacological therapy or other intervention (eg, use of an automated implantable cardioverter-defibrillator); hospitalization within the previous 12 months for heart failure functional classes III (marked limitation of activity and only comfortable at rest) and IV (need of complete rest, confinement to bed or chair, discomfort at
- •any physical activity, and presence of symptoms at rest) (New York Heart Association criteria [NYHA])
- •13. Subjects with a QTc (calculated according to Bazett?s formulae [QTc = QT/RR2], as indicated in the paper tracing generated by the equipment used to record the ECGs) above 470 milliseconds in the resting ECGs performed at Screening (Visit 1)
- •14. Subjects with clinically relevant abnormalities (as judged by the PI or Study Physician) in the results of the clinical laboratory tests, in ECG parameters other than QTc, or in the physical examination or vital signs at Screening (Visit 1) except for those related to COPD
- •15. Subjects who are HIV positive or have active viral hepatitis or other chronic systemic infection
- •16. Subjects with a history of drug or alcohol abuse within the previous 5 years
- •17. Subjects with any other serious or uncontrolled physical or mental condition/disease that, as judged by the Investigator, could place the subject at higher risk derived from his/her participation in the study, could confound the results of the study, or would be
- •likely to prevent the subject from complying with the requirements of the study or completing the study. If there is a history of such disease but the condition has been stable for more than 1 year and is judged by the PI not to interfere with the subject?s participation in the study, the subject may b
研究者
相似试验
进行中（未招募）
不适用
A 52 week study to investigate the effect of Roflumilast 500µg on worsening of symptoms, in subjects with COPD, a progressive disease that make it hard to breath. The subjects will be given Roflumilast 500 µg or Placebo in addition to their regular fixed dose combination medication of Long-Acting Beta Agonist and Inhaled Corticosteroid, that is used to open up the airways.Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2011-003606-24-ITFOREST RESEARCH INSTITUTE2,300
进行中（未招募）
1 期
Controlled Clinical Study of Dupilumab in Patients with Nasal PolypsBilateral nasal polyposisMedDRA version: 20.0 Level: PT Classification code 10028756 Term: Nasal polyps System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-001314-10-PTSANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT720
进行中（未招募）
1 期
Controlled Clinical Study of Dupilumab in Patients with Nasal PolypsEUCTR2015-001314-10-SESANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT720
进行中（未招募）
1 期
Controlled Clinical Study of Dupilumab in Patients with Nasal PolypsEUCTR2015-001314-10-BESANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT448
进行中（未招募）
1 期
Controlled Clinical Study of Dupilumab in Patients with Nasal PolypsBilateral nasal polyposisMedDRA version: 19.0 Level: PT Classification code 10028756 Term: Nasal polyps System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-001314-10-ESSANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT720